Small molecule inhibitor of c-Met (PHA665752) suppresses the growth of ovarian cancer cells and reverses cisplatin resistance

Functional Expression and Mutations of c-Met and Its Therapeutic Inhibition with SU11274 and Small Interfering RNA in Non–Small Cell Lung Cancer

C. Patrick, Ramasamy Jagadeeswaran, Simha Jagadeesh et al. · Cancer Research · 2005 · 578 citations

Medicine, Oncology, Pharmacology +14

A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo.

James G. Christensen, Randall Schreck, Jon Burrows et al. · PubMed · 2003 · 497 citations

Medicine, Oncology, Pharmacology +15

Amplification of <i>MET</i> may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752

Gromoslaw A. Smolen, Raffaella Sordella, Beth Muir et al. · Proceedings of the National Academy of Sciences · 2006 · 484 citations · Full text

Medicine, Cancer Biology, Oncology +17

c-Met Overexpression Is a Prognostic Factor in Ovarian Cancer and an Effective Target for Inhibition of Peritoneal Dissemination and Invasion

Kenjiro Sawada, A. Reza Radjabi, Nariyoshi Shinomiya et al. · Cancer Research · 2007 · 260 citations

Medicine, Cancer Biology, Oncology +17

A Selective Small Molecule Inhibitor of c-Met, PHA665752, Inhibits Tumorigenicity and Angiogenesis in Mouse Lung Cancer Xenografts

Neelu Puri, Andrey Khramtsov, Salman Ahmed et al. · Cancer Research · 2007 · 126 citations

Medicine, Oncology, Pharmacology +15